Merck & Co., Inc. announced their candidate AIDS vaccine failed to provide protection in a human study designed to test for efficacy. In this Merck trial involving high risk volunteers, an equal number of people received either placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be stopped because it was not reaching its efficacy endpoints.
Vaccination in a phase II clinical trial of Merck & Co., Inc.’s investigational HIV vaccine (V520) is being discontinued because the vaccine was not effective.
Tibotec Pharmaceuticals Ltd. announced that the New Drug Application (NDA) for TMC125 (etravirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), has been accepted for priority review by the United States Food and Drug Administration (FDA).
Repeated courses of a drug that is used to improve the survival of unborn premature babies also may increase the risk of cerebral palsy in those children, according to results from a multi-center study, funded by the National Institutes of Health and led by Ronald Wapner, M.D., professor of obstetrics and gynecology, Columbia University Medical Center and attending obstetrician and gynecologist at NewYork-Presbyterian Hospital/Columbia.
A new study being published in the Sept. 15 issue of Biological Psychiatry reports that genetic variation in a particular enzyme affects the success rates of treatment with bupropion, an antismoking drug.
Iomai Corporation (Nasdaq: IOMI) announced that travelers who received the company’s patch-based travelers’ diarrhea vaccine were significantly less likely to be sickened as compared with travelers who receive a placebo, according to research presented today by Chief Scientific Officer Gregory Glenn, M.D. at a late-breaker presentation during the “Vaccines and Pediatric Infections” session of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy being held in Chicago.
The U.S. Food and Drug Administration approved expanding the population for use of the nasal influenza vaccine FluMist to include children between the ages of 2 and 5.
Uncontrolled patients with type 2 diabetes treated with metformin, one of the most prescribed oral medicines for this disease, were four times more likely to achieve recommended blood sugar control levels by adding Galvus® (vildagliptin) to their treatment compared to those who added a placebo, according to new clinical data[1].
Results of the first-ever clinical study in patients with osteoporosis who suffered a hip fracture show that a once-yearly infusion of Aclasta®/Reclast® (zoledronic acid 5 mg)[*] reduced the risk of subsequent fractures by 35% compared to patients treated with placebo.
Whether a smoking-cessation drug will enable you to quit smoking may depend on your genes, according to new genotyping research from the Centre for Addiction and Mental Health (CAMH). The study, published in the September issue of the journal Biological Psychiatry, found that the enzyme known to metabolize both the smoking cessation drug bupropion and nicotine is highly genetically variable in all ethnicities and influences smoking cessation.